The Laryngoscope · 2025
Branchial Cleft Cyst Carcinoma Remains Grossly Over Diagnosed: A Large Database Analysis.
СтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Meci Andrew, Goyal Neerav, Goldenberg David
Аннотация
INTRODUCTION: Branchial cleft cyst carcinomas (BCCC) are rare lateral neck malignancies thought to originate from branchial cleft remnants. Diagnosing primary BCCC should be approached with skepticism; cystic nodal metastasis must be excluded. Due to its rarity, we performed a comprehensive database study to better characterize the ongoing diagnosis of BCCC.
METHODS: Single-arm retrospective cohort study using the TriNetX Research database. Patients ≥ 18 years of age with a diagnosis of BCCC identified by ICD-10 C10.4 between 2008 and 2018 were included, allowing for up to 5 years of follow-up. Demographics, past medical history, oncologic history, diagnostic rate, treatment pathways, and 5-year outcomes including diagnosis with primary HNC and Kaplan-Meier survival curves were analyzed within TriNetX.
RESULTS: In 10 years, 1070 patients diagnosed with BCCC were included. The mean age was 59.6 ± 9.7; the majority were male (n = 810, 75.6%) and white (n = 765, 71.4%). Incidence of BCCC increased from 2008 to 2015 and subsequently dropped precipitously. Almost all patients, 94.4% (n = 1011), had prior or subsequent diagnosis of another HNC within 5 years. Five-year survival probability for BCCC was 56.0%.
CONCLUSIONS: We describe the largest cohort of BCCC patients to date. Most patients were diagnosed with another HNC within 5 years, suggesting a likely misdiagnosis of BCCC. A poor 5-year survival rate may be secondary to a delay in appropriate treatment following an erroneous diagnosis, underscoring the need to approach a diagnosis of BCCC with caution. We consider the use of the BCCC code to be detrimental and recommend its discontinuation.
METHODS: Single-arm retrospective cohort study using the TriNetX Research database. Patients ≥ 18 years of age with a diagnosis of BCCC identified by ICD-10 C10.4 between 2008 and 2018 were included, allowing for up to 5 years of follow-up. Demographics, past medical history, oncologic history, diagnostic rate, treatment pathways, and 5-year outcomes including diagnosis with primary HNC and Kaplan-Meier survival curves were analyzed within TriNetX.
RESULTS: In 10 years, 1070 patients diagnosed with BCCC were included. The mean age was 59.6 ± 9.7; the majority were male (n = 810, 75.6%) and white (n = 765, 71.4%). Incidence of BCCC increased from 2008 to 2015 and subsequently dropped precipitously. Almost all patients, 94.4% (n = 1011), had prior or subsequent diagnosis of another HNC within 5 years. Five-year survival probability for BCCC was 56.0%.
CONCLUSIONS: We describe the largest cohort of BCCC patients to date. Most patients were diagnosed with another HNC within 5 years, suggesting a likely misdiagnosis of BCCC. A poor 5-year survival rate may be secondary to a delay in appropriate treatment following an erroneous diagnosis, underscoring the need to approach a diagnosis of BCCC with caution. We consider the use of the BCCC code to be detrimental and recommend its discontinuation.